2010
DOI: 10.4161/viru.1.4.11833
|View full text |Cite
|
Sign up to set email alerts
|

Evidence-based practice: Management of Combined Toxoplasma meningo-encephalitis and Pneumocystis pneumonia in HIV

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 7 publications
0
2
0
Order By: Relevance
“…Although a drastic decrease has been observed both for non-CNS disease and CNS infections, P. jirovecii and T. gondii remain common opportunistic infectious agents. However, to our knowledge, reports of patients presenting with combined pulmonary and/or cerebral toxoplasmosis and pneumocystis infection are scarce [ 11 , 12 ]. Pulmonary toxoplasmosis (PT) has become a very rare parasitic infection since the advent of highly active antiretroviral therapies.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Although a drastic decrease has been observed both for non-CNS disease and CNS infections, P. jirovecii and T. gondii remain common opportunistic infectious agents. However, to our knowledge, reports of patients presenting with combined pulmonary and/or cerebral toxoplasmosis and pneumocystis infection are scarce [ 11 , 12 ]. Pulmonary toxoplasmosis (PT) has become a very rare parasitic infection since the advent of highly active antiretroviral therapies.…”
Section: Discussionmentioning
confidence: 99%
“…However, no case series have shown the efficacy of TMP-SMX alone for treating P. jirovecii and T. gondii co-infection. Bruck et al [ 12 ] summarized the recommendations for the management of combined PCP and TE based on 4 case reports of patients treated by (i) TMP-SMX + pyrimethamine + sulfadiazine, (ii) atovaquone + pyrimethamine + sulfadiazine, (iii) TMP-SMX + pyrimethamine + clindamycin, and (iv) pyrimethamine + clindamycin + primaquine. Clearly, the treatment choice should aim for the lowest toxicity.…”
Section: Discussionmentioning
confidence: 99%